T J Walsh

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi New targets and delivery systems for antifungal therapy
    T J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Med Mycol 38:335-47. 2000
  2. ncbi Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients
    T J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bldg 10, Rm 13N 240, Bethesda, MD 20892, USA
    Int J Antimicrob Agents 16:151-6. 2000
  3. pmc Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction
    Thomas J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Clin Microbiol 42:4744-8. 2004
  4. pmc Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans
    Vidmantas Petraitis
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Rm 13N240, Center Dr, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 48:3959-67. 2004
  5. pmc Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration
    Thomas J Walsh
    Pediatric Oncology Branch, National Cancer Institute, Bldg 10, Rm 13N240, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 48:2166-72. 2004
  6. ncbi Infections due to emerging and uncommon medically important fungal pathogens
    T J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, The National Cancer Institute, Bethesda, MD 20892 1928, USA
    Clin Microbiol Infect 10:48-66. 2004
  7. ncbi Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B
    Thomas J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, NIH Building 10, Room 13N240, Bethesda, MD 20892, USA
    J Infect Dis 188:305-19. 2003
  8. pmc Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study
    T J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 45:3487-96. 2001
  9. doi Diagnostic imaging of experimental invasive pulmonary aspergillosis
    Thomas J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Med Mycol 47:S138-45. 2009
  10. ncbi Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
    Thomas J Walsh
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Pediatr Infect Dis J 21:240-8. 2002

Collaborators

Detail Information

Publications116 found, 100 shown here

  1. ncbi New targets and delivery systems for antifungal therapy
    T J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Med Mycol 38:335-47. 2000
    ..The ongoing convergence of the fields of molecular pathogenesis, antifungal pharmacology and vaccine development will afford the opportunity to develop novel targets to complement the existing antifungal armamentarium...
  2. ncbi Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients
    T J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bldg 10, Rm 13N 240, Bethesda, MD 20892, USA
    Int J Antimicrob Agents 16:151-6. 2000
    ....
  3. pmc Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction
    Thomas J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Clin Microbiol 42:4744-8. 2004
    ....
  4. pmc Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans
    Vidmantas Petraitis
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Rm 13N240, Center Dr, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 48:3959-67. 2004
    ..In summary, PLD-118 demonstrated dosage-dependent antifungal activity and nonlinear plasma pharmacokinetics in treatment of experimental FLC-resistant oropharyngeal and esophageal candidiasis...
  5. pmc Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration
    Thomas J Walsh
    Pediatric Oncology Branch, National Cancer Institute, Bldg 10, Rm 13N240, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 48:2166-72. 2004
    ....
  6. ncbi Infections due to emerging and uncommon medically important fungal pathogens
    T J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, The National Cancer Institute, Bethesda, MD 20892 1928, USA
    Clin Microbiol Infect 10:48-66. 2004
    ..The medical community is thus called upon to acquire an understanding of the microbiology, epidemiology and pathogenesis of these previously uncommon pathogens in order to become familiar with the options for prevention and treatment...
  7. ncbi Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B
    Thomas J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, NIH Building 10, Room 13N240, Bethesda, MD 20892, USA
    J Infect Dis 188:305-19. 2003
    ..The hyphae of A. terreus in vivo displayed distinctive aleurioconidia, which may be a practical microscopic feature for rapid preliminary diagnosis...
  8. pmc Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study
    T J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 45:3487-96. 2001
    ..These findings indicate that L-AMB at dosages as high as 15 mg/kg/day follows nonlinear saturation-like kinetics, is well tolerated, and can provide effective therapy for aspergillosis and other filamentous fungal infections...
  9. doi Diagnostic imaging of experimental invasive pulmonary aspergillosis
    Thomas J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Med Mycol 47:S138-45. 2009
    ..MDVI also improves objectivity of radiological assessment of therapeutic response to antifungal therapy and merits more extensive evaluation in patients with invasive aspergillosis, as well as other fungal and bacterial pneumonias...
  10. ncbi Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
    Thomas J Walsh
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Pediatr Infect Dis J 21:240-8. 2002
    ..To describe the safety and efficacy of voriconazole in children treated within the compassionate release program...
  11. pmc Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits
    T J Walsh
    Mycology Unit and Immunocompromised Host Section, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 44:2068-76. 2000
    ..The study describes a detailed model of the pharmacokinetics of ABLC and characterizes a potential role of the cellular components of the blood-sediment compartment in the distribution of this new antifungal compound in tissue...
  12. pmc Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis
    T J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Clin Microbiol 38:2369-73. 2000
    ..albicans versus untreated controls. We conclude that there is a strong correlation between in vitro fluconazole susceptibility by NCCLS methods and in vivo response to fluconazole therapy of OPEC due to C. albicans...
  13. ncbi Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial
    Thomas J Walsh
    Immunocompromised Host Section, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Infect Dis 44:2-12. 2007
    ..Current treatments provide limited benefit. Posaconazole is an extended-spectrum triazole with in vitro and in vivo activity against Aspergillus species...
  14. pmc Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents
    Thomas J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bldg 10 CRC, Room 1W 5750, 10 Center Drive, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 49:4536-45. 2005
    ..These results demonstrate that caspofungin at 1 mg/kg/day in pediatric patients is suboptimal. Caspofungin administration at 50 mg/m2/day provides a comparable exposure to that of adult patients treated with 50 mg/day...
  15. ncbi Control, immunoregulation, and expression of innate pulmonary host defenses against Aspergillus fumigatus
    T J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bldg 10, Rm 13N 240, 10 Center Drive, Bethesda, MD 20892, USA
    Med Mycol 43:S165-72. 2005
    ....
  16. doi Pneumocystis pneumonia in children
    Vasilios Pyrgos
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Paediatr Respir Rev 10:192-8. 2009
    ..Prophylaxis of high-risk patients reduces but does not eliminate the risk of PCP. Improved understanding of the pathogenesis of PCP is important for future advances against this life-threatening infection...
  17. pmc Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling
    A H Groll
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute/NIH, 10 Center Dr, Building 10, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 45:2845-55. 2001
    ....
  18. pmc Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia
    Ruta Petraitiene
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 46:12-23. 2002
    ....
  19. pmc Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits
    Ruta Petraitiene
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 48:1188-96. 2004
    ..Intravenously administered ravuconazole lysine phosphoester showed dose-dependent efficacy and an excellent safety profile for the treatment of invasive pulmonary aspergillosis in persistently neutropenic rabbits...
  20. pmc Transmission of an azole-resistant isogenic strain of Candida albicans among human immunodeficiency virus-infected family members with oropharyngeal candidiasis
    F M Muller
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Microbiol 37:3405-8. 1999
    ..This study contributes to an evolving understanding of the mode of transmission of C. albicans, particularly in children, and underscores the importance of monitoring specimens from family members of HIV-infected patients...
  21. pmc Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits
    A H Groll
    Immunocompromised Host Section, Pediatric Oncology Branch National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 45:3322-7. 2001
    ..18 microg/g. These findings indicate linear disposition of micafungin at dosages of 0.5 to 2 mg/kg and achievement of potentially therapeutic drug concentrations in plasma and tissues that are common sites of invasive fungal infections...
  22. ncbi Increased adherence of fluconazole-resistant isolates of Candida species to explanted esophageal mucosa
    C A Lyman
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Eur J Clin Microbiol Infect Dis 18:213-6. 1999
    ..001) and to all Candida spp. tested (P<0.001). Thus, the refractoriness of esophageal candidiasis in patients infected with fluconazole-resistant isolates may be related to both in vitro drug resistance and increased mucosal adherence...
  23. ncbi Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus
    C E Gonzalez
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Cytokine 15:87-95. 2001
    ..fumigatus and suggest a potential role for this cytokine as adjunctive therapy in the treatment of pulmonary aspergillosis in the setting of profound neutropenia...
  24. pmc Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits
    Ruta Petraitiene
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892 1100, USA
    Antimicrob Agents Chemother 49:2084-92. 2005
    ..Icofungipen followed dose-dependent pharmacokinetics and was effective in the treatment of experimental disseminated candidiasis, including central nervous system infection, in persistently neutropenic rabbits...
  25. ncbi Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation
    Joseph Meletiadis
    Immunocompromised Host Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Infect Dis 194:1008-18. 2006
    ..No pharmacokinetic interaction was found. The combination of a triazole and polyene may be antagonistic in the treatment of invasive pulmonary aspergillosis...
  26. ncbi Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin
    Vidmantas Petraitis
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 187:1834-43. 2003
    ..The combination of an antifungal triazole and echinocandin may represent a new strategy for treatment of invasive pulmonary aspergillosis...
  27. ncbi Micafungin: pharmacology, experimental therapeutics and clinical applications
    Andreas H Groll
    Pediatric Oncology Branch, National Cancer Institute, Building 10, Room 1 3888, National Institutes of Health, Bethesda, MD 20892, USA
    Expert Opin Investig Drugs 14:489-509. 2005
    ..This paper reviews the preclinical and clinical pharmacology of micafungin and its potential role for treatment of fungal invasive infections in patients...
  28. pmc Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits
    Vidmantas Petraitis
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 46:1857-69. 2002
    ..albicans from persistently neutropenic rabbits with disseminated candidiasis but not of A. fumigatus from persistently neutropenic rabbits with invasive pulmonary aspergillosis...
  29. ncbi Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
    Thomas J Walsh
    National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 346:225-34. 2002
    ..Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer and effective alternative...
  30. ncbi Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis
    Theodouli Stergiopoulou
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Clin Pathol 127:349-55. 2007
    ..Thus, the status of innate host defenses contributes significantly to the histologic patterns observed in IPA...
  31. pmc Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology
    Joseph Meletiadis
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 51:3329-37. 2007
    ....
  32. ncbi Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy
    William W Hope
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 195:455-66. 2007
    ..Little is known about the pathogenesis of invasive pulmonary aspergillosis and the relationship between the kinetics of diagnostic markers and the outcome of antifungal therapy...
  33. pmc Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus
    M Simitsopoulou
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bldg 10, CRC 1 5750, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 51:1048-54. 2007
    ..01). These results demonstrate that in the presence of VRC, HF induces a more pronounced profile of gene expression in THP-1 cells than HF alone, potentially leading to more-efficient host resistance to A. fumigatus...
  34. pmc Effects of the hematoregulatory peptide SK&F 107647 alone and in combination with amphotericin B against disseminated candidiasis in persistently neutropenic rabbits
    C A Lyman
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 43:2165-9. 1999
    ..These data suggest a potential role for this peptide as adjunctive therapy in combination with conventional antifungal agents in the treatment of disseminated candidiasis in the setting of profound and persistent neutropenia...
  35. ncbi Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factor
    E Roilides
    Infectious Diseases Section, National Cancer Institute, Bethesda, Maryland 20892
    J Pediatr 117:531-40. 1990
    ....
  36. ncbi Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century
    T J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Transpl Infect Dis 1:247-61. 1999
    ....
  37. pmc Effect of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates
    K E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1928, USA
    Antimicrob Agents Chemother 44:1100-1. 2000
    ..Fluconazole pretreatment had no effect on doxorubicin pharmacokinetics...
  38. pmc The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates
    William W Hope
    Immunocompromised Host Section, Pediatric Oncology Branch, CRC, Rm 1 5750, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 197:163-71. 2008
    ..The outcome after antifungal therapy is often suboptimal, with few therapeutic options. Limited clinical data suggest that echinocandins may have role to play in the treatment of HCME...
  39. ncbi Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species
    Elizabeth M O'Shaughnessy
    Immunocompromised Host Section, Pediatric Oncology Branch, Clinical Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Antimicrob Chemother 58:1168-76. 2006
    ..The in vitro effects of caspofungin combined with voriconazole and amphotericin B were tested in triplicate experiments against nine clinical isolates of Aspergillus fumigatus, Aspergillus flavus and Aspergillus terreus...
  40. ncbi Advances in antifungal therapy
    Pia S Pannaraj
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Pediatr Infect Dis J 24:921-2. 2005
  41. pmc Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model
    Joseph Meletiadis
    National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 51:2053-64. 2007
    ..In conclusion, the new nonlinear mixture-amount response surface modeling of the triple antifungal combination demonstrated a net antagonism or synergy against Aspergillus species depending upon drug concentrations and species...
  42. pmc Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis
    Andrea Francesconi
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bldg 10 CRC, Rm 1 5740, Bethesda, MD 20892, USA
    J Clin Microbiol 44:2475-80. 2006
    ..04). Use of the GM EIA and qPCR assay in conjunction with culture-based diagnostic methods applied to BAL fluid could facilitate accurate diagnosis and more-timely initiation of specific therapy...
  43. pmc Invasive infection with Fusarium chlamydosporum in a patient with aplastic anemia
    B H Segal
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Microbiol 36:1772-6. 1998
    ..chlamydosporum. This case illustrates the ever-increasing spectrum of pathogenic Fusarium spp. in immunocompromised patients and emphasizes the potential pitfalls in histologic diagnosis, which may have important treatment implications...
  44. pmc Rapid extraction of genomic DNA from medically important yeasts and filamentous fungi by high-speed cell disruption
    F M Muller
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Microbiol 36:1625-9. 1998
    ..We conclude that mechanical disruption of fungal cells by HSCD is a safe, rapid, and efficient procedure for extracting genomic DNA from medically important yeasts and especially from filamentous fungi...
  45. ncbi High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial
    J F Tisdale
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Lancet 356:1554-9. 2000
    ....
  46. ncbi Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections
    A H Groll
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Rm 13 N240, 10 Center Drive, Bethesda, MD 20892, USA
    Expert Opin Investig Drugs 10:1545-58. 2001
    ..This paper reviews the preclinical and clinical pharmacology of caspofungin and its potential role for treatment of invasive and superficial fungal infections in patients...
  47. pmc Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients
    T J Walsh
    Pediatric Oncology Branch, National Institutes of Health, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 42:2391-8. 1998
    ....
  48. ncbi Uncommon opportunistic fungi: new nosocomial threats
    A H Groll
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Microbiol Infect 7:8-24. 2001
    ....
  49. ncbi Keratitis caused by Candida glabrata in a patient with chronic granulomatous disease
    A R Djalilian
    National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892 1863, USA
    Am J Ophthalmol 132:782-3. 2001
    ..To report an unusual ocular presentation of Candida glabrata in a patient with chronic granulomatous disease...
  50. ncbi Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo
    A H Groll
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Pharmacotherapy 21:133S-148S. 2001
    ....
  51. pmc Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients
    Nita L Seibel
    Pediatric Oncology Branch, National Cancer Institute, Bldg 10, Rm 13N 240, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 49:3317-24. 2005
    ..In summary, micafungin over a dosage range between 0.5 and 4.0 mg/kg/day in 77 febrile neutropenic pediatric patients displayed linear pharmacokinetics and increased clearance as a function of decreasing age...
  52. pmc Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis
    Vidmantas Petraitis
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Building 10, Rm 1W 5750, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 53:2382-91. 2009
    ....
  53. ncbi Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits
    Andreas H Groll
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, CRTC 1 575, Bethesda, MD 20892, USA
    J Antimicrob Chemother 56:899-907. 2005
    ..We investigated the compartmental plasma pharmacokinetics and tissue distribution of ravuconazole following administration of its novel intravenous (i.v.) di-lysine phosphoester prodrug, BMS-379224...
  54. pmc Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis
    Vidmantas Petraitis
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Building 10, CRC, Rm 1W 5740, 10 Center Dr, MSC 1100, Bethesda, Maryland 20892 1100, USA
    Antimicrob Agents Chemother 49:1642-5. 2005
    ..Fungizone and generic amphotericin B are similar in efficacy, pharmacokinetics, and safety in the treatment of experimental IPA...
  55. doi Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp
    Joanne P Demchok
    Immunocompromised Host Section, National Cancer Institute, Bethesda, MD 20892 1928, USA
    Mycoses 53:239-45. 2010
    ..fumigatus and A. flavus, while it increased the synergy against A. terreus...
  56. pmc Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis
    Ruta Petraitiene
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1100, USA
    Antimicrob Agents Chemother 52:4121-9. 2008
    ..842). Micafungin demonstrated dose-dependent and site-dependent activity against HCME. CSF beta-glucan may be a useful biomarker for detection and monitoring of therapeutic response in HCME...
  57. pmc Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis
    Andreas H Groll
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute NIH, Building 10, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 46:2554-63. 2002
    ..Based on this documented safety and efficacy, a dosage of 2.5 mg/kg BID can be recommended for the treatment of OPC in pediatric patients > or =5 years old...
  58. ncbi Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia
    Thomas J Walsh
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 351:1391-402. 2004
    ..Caspofungin, a member of the new echinocandin class of compounds, may be an effective alternative that is better tolerated than amphotericin B...
  59. pmc Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis
    Vidmantas Petraitis
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Building 10, CRC, Rm 1W 5740, 10 Center Dr, MSC 1100, Bethesda, MD 20892 1100, USA
    Antimicrob Agents Chemother 50:1510-7. 2006
    ....
  60. pmc Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus
    C C Chiou
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 45:3310-21. 2001
    ..In summary, these two cell wall-targeted antifungal agents, FK and NZ, showed marked time-dependent in vitro synergistic activity against A. fumigatus...
  61. pmc Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis
    William W Hope
    Pediatric Oncology Branch, NCI NIH, CRC Room 1 5750, 10 Center Dr, MSC 1100, Bethesda, MD 20892 1100, USA
    Antimicrob Agents Chemother 51:285-95. 2007
    ..Neutrophils and the timely initiation of antifungal agents are critical determinants in the treatment of experimental disseminated candidiasis...
  62. pmc Fusarium proliferatum soft tissue infection at the site of a puncture by a plant: recovery, isolation, and direct molecular identification
    Tara N Palmore
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Clin Microbiol 48:338-42. 2010
    ..Amplification of the internal transcribed spacer region and 5.8S rRNA, beta-tubulin, and translation elongation factor coding genes identified Fusarium proliferatum, which was confirmed later by culture...
  63. pmc Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect
    William W Hope
    Pediatric Oncology Branch, NCI NIH, CRC Rm 1 5750, 10 Center Dr, MSC 1100, Bethesda MD 20892 1100, USA
    Antimicrob Agents Chemother 50:3680-8. 2006
    ..The in vivo growth rate was a critical additional determinant of the exposure-response relationship. There was a relationship between the 5FC resistance genotype and the exposure-response relationship...
  64. pmc Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species
    Charalampos Antachopoulos
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 51:881-7. 2007
    ..Assessment of metabolic activity may provide useful quantitative endpoints for in vitro studies of caspofungin against Aspergillus spp...
  65. pmc Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus
    Theodouli Stergiopoulou
    Immunocompromised Host Section, Pediatric Oncology Branch, Clinical Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Antimicrob Chemother 63:343-8. 2009
    ..However, little is known about the interaction between other extended-spectrum fluoroquinolones, such as levofloxacin and moxifloxacin, and antifungal agents against C. albicans and A. fumigatus...
  66. pmc Pharmacokinetics of liposomal amphotericin B in pleural fluid
    Brad Moriyama
    NIH Clinical Center Pharmacy Department, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 54:1633-5. 2010
    ..4%, with pleural fluid concentrations of 2.12 to 4.91 microg/ml. Given the relatively low level of intrapleural penetration of liposomal amphotericin B, chest tube drainage may be warranted for successful treatment of zygomycotic empyema...
  67. pmc Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing
    William W Hope
    Pediatric Oncology Branch, NCI NIH, CRC Room 1 5750, Bethesda, MD 20892 1100, USA
    Antimicrob Agents Chemother 51:3714-9. 2007
    ....
  68. pmc High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients
    Brad Moriyama
    National Institutes of Health Clinical Center Pharmacy Department, Bethesda, MD 20892, USA
    Ann Pharmacother 44:929-35. 2010
    ..To report a case series of high-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections...
  69. doi Successful treatment of periodontal mucormycosis: report of a case and literature review
    Nancy E McDermott
    National Institute of Dental and Craniofacial Research, Bethesda, Maryland 20892, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109:e64-9. 2010
    ..Calcofluor fluorescence microscopy is also proposed as a method for establishing a prompt diagnosis and guiding extent of intraoperative surgical debridement...
  70. pmc Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus
    Theodouli Stergiopoulou
    Immunocompromised Host Section, Pediatric Oncology Branch, Clinical Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 52:2196-204. 2008
    ..fumigatus. Isobolographic analysis may help to elucidate the pharmacodynamic interactions between antifungal and non-antifungal agents and to develop better management strategies against invasive candidiasis and aspergillosis...
  71. ncbi The pharmacology and clinical use of caspofungin
    William W Hope
    National Institutes of Health, 10 Center Dr, Bethesda, MD, 20892, USA
    Expert Opin Drug Metab Toxicol 3:263-74. 2007
    ....
  72. pmc Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp
    Joanne Peter
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Building 10, Room 13N240, 10 Center Drive, Bethesda, MD 20892 1928, USA
    J Clin Microbiol 43:3788-92. 2005
    ..05). The use of fluorescent probes provides a mechanism-based method of determination of MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp. that correlates well with standard methods...
  73. pmc Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia
    Charalampos Antachopoulos
    Pediatric Oncology Branch, National Cancer Institute, CRC, Rm 1 5750, MSC 1100, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 52:321-8. 2008
    ..The paradoxical increase in metabolism occurred more frequently and at lower concentrations with caspofungin than with micafungin and anidulafungin...
  74. pmc Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations
    Andreas H Groll
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 50:3418-23. 2006
    ..Whereas the disposition of ABCD was overall not fundamentally different from that of DAMB, ABLC showed prominent accumulation in lung tissue and PAM, while LAMB achieved the highest concentrations in ELF...
  75. ncbi Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils
    E Roilides
    Infectious Diseases Section, Pediatric Branch, National Cancer Institute, Bethesda, MD 20892
    J Infect Dis 163:579-83. 1991
    ..albicans blastoconidia. These data demonstrate that G-CSF enhances the antibacterial but not the antifungal activities of human PMNL in vitro and also improves the defective PMNL bactericidal activity of HIV-1-infected patients...
  76. ncbi Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus
    F M Muller
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Eur J Pediatr 158:187-99. 1999
    ..Immunmodulation by recombinant cytokines and antifungal vaccines are very actively pursued inroads to adjunctive and preventive immunotherapy...
  77. pmc Invasive candidiasis stimulates hepatocyte and monocyte production of active transforming growth factor beta
    J J Letterio
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Infect Immun 69:5115-20. 2001
    ..albicans infection that most probably contributes to disease progression in the immunocompromised host...
  78. ncbi Cyclosporine A-induced mammary hyperplasia and hyperprolactinemia in New Zealand White rabbits
    R Petraitiene
    Immunocompromised Host Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Comp Med 51:430-5. 2001
    ..This rabbit model may be a reliable in vivo system by which to study immunosuppressant-induced structural and functional changes of mammary glands similar to those observed in humans...
  79. pmc Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits
    Andreas H Groll
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, 20892, USA
    Antimicrob Agents Chemother 47:3917-25. 2003
    ..Based on its enhanced urinary exposure, LNYS may offer a therapeutic advantage in systemic fungal infections involving the upper and lower urinary tracts that require therapy with antifungal polyenes...
  80. pmc Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients
    Thomas J Walsh
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 54:3451-9. 2010
    ..fumigatus for 24 h and that these concentrations would continue to increase during 14 days of administration, supporting its potential activity for prevention and early treatment of pulmonary aspergillosis...
  81. doi Pharmacology and antifungal properties of anidulafungin, a new echinocandin
    Kristina E Estes
    Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 29:17-30. 2009
    ..The safety, tolerability, and potent fungicidal activity of anidulafungin against Candida species make it a reasonable alternative in the treatment of patients with serious candidal infections...
  82. doi Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria
    Brad Moriyama
    Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD, USA
    Ann Pharmacother 43:1324-37. 2009
    ..To describe the rationale, principles, and dosage calculations for continuous-infusion beta-lactam antibiotics to treat multidrug-resistant bacteria in patients undergoing continuous venovenous hemofiltration (CVVH)...
  83. ncbi Galactomannan antigen detection in the diagnosis of invasive aspergillosis
    Virginia Verdaguer
    National Cancer Institute, Immunocompromissed Host Section, Pediatric Oncology Branch, National Institutes of Health, 9000 Rockville Pike 10, Center Dr CRC 1 W 5752, Bethesda, MD 20892 1100, USA
    Expert Rev Mol Diagn 7:21-32. 2007
    ..As an adjunct in the diagnosis and management of invasive aspergillosis, incorporation of the galactomannan enzyme immunoassay into clinical trials will help to further define its role...
  84. pmc Use of quantitative real-time PCR to study the kinetics of extracellular DNA released from Candida albicans, with implications for diagnosis of invasive Candidiasis
    Miki Kasai
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Microbiol 44:143-50. 2006
    ..albicans DNA...
  85. ncbi Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani
    Emmanuel Roilides
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MA, USA
    Mycoses 49:109-13. 2006
    ..solani. On the contrary, at a concentration of 0.125 microg ml(-1), ABLC and, to a lesser degree, DAMB additively augmented the fungicidal activity of pulmonary alveolar macrophages against conidia of Fusarium solani...
  86. pmc Automated and manual methods of DNA extraction for Aspergillus fumigatus and Rhizopus oryzae analyzed by quantitative real-time PCR
    Andrea Francesconi
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Microbiol 46:1978-84. 2008
    ..fumigatus conidia and GHE. For R. oryzae, the automated method was more sensitive for DNA extraction of sporangiospores, while the manual method was more sensitive for GHE in BAL fluid...
  87. pmc Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis
    Miki Kasai
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Building 10 CRC, Room 1 5740, Bethesda, MD 20892, USA
    J Clin Microbiol 46:3690-702. 2008
    ..These qPCR assays are sensitive and specific for the detection of Rhizopus, Mucor, Rhizomucor, and Cunninghamella species and can be used for the study and detection of infections caused by these life-threatening pathogens...
  88. ncbi Successful treatment of coccidioidal meningitis with voriconazole
    Karoll J Cortez
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1882, USA
    Clin Infect Dis 36:1619-22. 2003
    ..The patient had photosensitivity after 10 weeks of treatment, but this improved when the voriconazole dose was lowered. Continuous voriconazole therapy kept coccidioidal meningitis in complete remission in this patient for >2 years...
  89. pmc Infections caused by Scedosporium spp
    Karoll J Cortez
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Clin Microbiol Rev 21:157-97. 2008
    ..By comparison, infections caused by S. prolificans seldom respond to medical therapy alone. Surgery and reversal of immunosuppression may be the only effective therapeutic options for infections caused by S. prolificans...
  90. doi Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America
    Thomas J Walsh
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Clin Infect Dis 46:327-60. 2008
  91. pmc Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy
    Jason W Lane
    Microbiology Service, Department of Laboratory Medicine, W G Magnuson Clinical Center, NIH, Bethesda, Maryland, USA
    Clin Chim Acta 387:145-9. 2008
    ..75 mmol/l in the absence of hypocalcemia and tissue deposition of calcium phosphate were noted in 3 patients receiving liposomal amphotericin B (L-AMB). We investigated L-AMB as a possible cause of pseudohyperphosphatemia...
  92. ncbi Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species
    Charalampos Antachopoulos
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Antimicrob Chemother 59:230-7. 2007
    ..To develop and evaluate a new method for rapid susceptibility testing of Aspergillus spp. based on early metabolic signalling of high-inoculum biomass...
  93. ncbi MK-0991 (Merck & Co)
    A H Groll
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20891, USA
    IDrugs 2:1201-12. 1999
    ..Peak annual sales of 500 million USD (US) and 500 million USD (ex-US) are predicted in 2008...
  94. pmc Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing
    William W Hope
    Department of Medicine, The University of Manchester, 1 800 Stopford Building, Oxford Road, Manchester, UK
    Antimicrob Agents Chemother 51:3760-2. 2007
    ..Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect...
  95. ncbi Voriconazole treatment for less-common, emerging, or refractory fungal infections
    John R Perfect
    Department of Medicine and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Infect Dis 36:1122-31. 2003
    ..Voriconazole is an effective and well-tolerated treatment for refractory or less-common invasive fungal infections...
  96. ncbi Emerging and less common fungal pathogens
    Rhonda V Fleming
    Division of Infectious Diseases, Boston University Medical Center, Boston, MA, USA
    Infect Dis Clin North Am 16:915-33, vi-vii. 2002
    ....
  97. pmc Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum
    Cristina Gil-Lamaignere
    3rd Pediatric Department, Aristotle University, Hippokration Hospital, Thessaloniki GR 54642, Greece
    Antimicrob Agents Chemother 46:2234-7. 2002
    ..prolificans and S. apiospermum...
  98. ncbi Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts
    Brahm H Segal
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Infect Dis 44:402-9. 2007
    ..Finally, we discuss the implications of newer antifungal agents and diagnostic adjuncts in the design of future clinical trials to evaluate prophylaxis and early prevention strategies...
  99. pmc Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus
    Emmanuel Roilides
    3rd Department of Pediatrics, University of Thessaloniki, Hippokration Hospital, Thessaloniki GR 54642, Greece
    Antimicrob Agents Chemother 46:1974-6. 2002
    ..DAMB, ABLC, and liposomal amphotericin B similarly displayed additive effects with polymorphonuclear leukocytes in damaging the hyphal elements of A. fumigatus...
  100. ncbi Decisions about voriconazole versus liposomal amphotericin B
    Thomas J Walsh
    N Engl J Med 346:1499; author reply 1499. 2002
  101. pmc Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease
    Carly G Dennis
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Antimicrob Agents Chemother 50:422-7. 2006
    ..fumigatus challenge and also demonstrated unique features of CGD mice as a model for experimental aspergillosis...